BMS-986158

Catalog No.S9691

For research use only.

BMS-986158 is a potent inhibitor of BET with IC50s of 6.6 nM and 5 nM in NCI-H211 small cell lung cancer (SCLC) cells and MDA-MB231 triple negative breast cancer (TNBC) cells, respectively.

BMS-986158 Chemical Structure

CAS No. 1800340-40-2

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description BMS-986158 is a potent inhibitor of BET with IC50s of 6.6 nM and 5 nM in NCI-H211 small cell lung cancer (SCLC) cells and MDA-MB231 triple negative breast cancer (TNBC) cells, respectively.
Targets
BET [1]
(in NCI-H211 cells)
BET [1]
(in MDA-MB231 cells)
6.6  nM 5  nM
In vitro

BMS-986158 is a BET inhibitor. The IC50 in NCI-H211 small cell lung cancer (SCLC) cells and MDA-MB231 triple negative breast cancer (TNBC) cells is 6.6 nM and 5 nM, respectively.<sup><a class="sref" href="#s_ref">[1]</a></sup>

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 495.62
Formula

C30H33N5O2

CAS No. 1800340-40-2
Storage 3 years -20°C powder
2 years -80°C in solvent

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03936465 Recruiting Drug: BMS-986158|Drug: BMS-986378 Solid Tumor Childhood|Lymphoma|Brain Tumor Pediatric Dana-Farber Cancer Institute|Stand Up To Cancer September 27 2019 Phase 1
NCT02419417 Completed Drug: BMS-986158|Biological: Nivolumab Advanced Tumors Bristol-Myers Squibb June 19 2015 Phase 1|Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy BMS-986158 | BMS-986158 supplier | purchase BMS-986158 | BMS-986158 cost | BMS-986158 manufacturer | order BMS-986158 | BMS-986158 distributor